Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
25.5M
-
Shares change
-
-3.87M
-
Total reported value, excl. options
-
$136M
-
Value change
-
-$23.3M
-
Put/Call ratio
-
1.29
-
Number of buys
-
26
-
Number of sells
-
-26
-
Price
-
$5.34
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q3 2019
85 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q3 2019.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.5M shares
of 131M outstanding shares and own 19.48% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (5.17M shares), ORBIMED ADVISORS LLC (3.53M shares), Polar Capital LLP (3.31M shares), Consonance Capital Management LP (2.56M shares), GOLDMAN SACHS GROUP INC (1.65M shares), FRANKLIN RESOURCES INC (1.41M shares), FMR LLC (1.13M shares), BlackRock Inc. (911K shares), ACUTA CAPITAL PARTNERS, LLC (850K shares), and HealthCor Management, L.P. (832K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.